Author:
Cohen Arnon D.,Torres Tiago,Boehncke Wolf-Henning,de Rie Menno,Jullien Denis,Naldi Luigi,Ryan Caitriona,Strohal Robert,Skov Lone,van de Kerkhof Peter,van der Walt Joelle M.,Wu Jashin J.,Zachariae Claus,Puig Lluis,Young Helen
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. European Medicines Agency. Biosimilar medicines. 2018
https://www.ema.europa.eu/en/humanregulatory/overview/biosimilar-medicines
. Accessed 12 Oct 2018.
2. Palmer SCSV, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, et al. The relative safety and effectiveness of different epoetin drugs for treating anaemia in people with chronic kidney disease. Cochrane Database Syst Rev. 2014;12:CD010590.
3. Combe CTR, Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy. 2005;25:954–62.
4. Hoivik ML, Buer LCT, Cvancarova M, Warren DJ, Bolstad N, Moum BA, et al. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-Centre IBD population. Scand J Gastroenterol. 2018;53(6):692–9.
https://doi.org/10.1080/00365521.2018.1463391
.
5. Inotai A, Prins CPJ, Csanadi M, Vitezic D, Codreanu C, Kalo Z. Is there a reason for concern or is it just hype? - a systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Expert Opin Biol Ther. 2017;17(8):915–26.
https://doi.org/10.1080/14712598.2017.1341486
.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献